In vitro and in vivo activities of linezolid alone and combined with vancomycin and imipenem against Staphylococcus aureus with reduced susceptibility to glycopeptides

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 29, Issue 11, 2010, Pages 1361-1367

  Ribes, S ^a   Pachon Ibanez M E ^a   Dominguez M A ^a   Fernandez R ^a   Tubau, F ^a   Ariza, J ^a   Gudiol, F ^a   Cabellos, C ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CEFOTAXIME; CILASTATIN PLUS IMIPENEM; CLOXACILLIN; LINEZOLID; POLYPEPTIDE ANTIBIOTIC AGENT; TEICOPLANIN; VANCOMYCIN;

ADD ON THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTEREMIA; BACTERIAL COUNT; BACTERIAL STRAIN; BACTERIAL SURVIVAL; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; BLOOD CULTURE; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; IN VITRO STUDY; IN VIVO STUDY; INOCULATION; MONOTHERAPY; MORTALITY; MOUSE; NONHUMAN; PERITONEAL FLUID; PERITONITIS; PRIORITY JOURNAL; RANDOMIZATION; SINGLE DRUG DOSE; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

ACETAMIDES; ANIMALS; ASCITIC FLUID; BACTEREMIA; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; GLYCOPEPTIDES; IMIPENEM; METHICILLIN RESISTANCE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICE; MICE, INBRED C57BL; MICROBIAL SENSITIVITY TESTS; OXAZOLIDINONES; PERITONITIS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

EID: 78449261915     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10096-010-1007-y     Document Type: Article

References (34)

1. TS Naimi KH LeDell K Como-Sabetti SM Borchardt DJ Boxrud J Etienne, et al. 2003 Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection JAMA 290 2976 2984 1:CAS:528:DC%2BD3sXpvVKhtbg%3D 10.1001/jama.290.22.2976 14665659
2. SE Cosgrove G Sakoulas EN Perencevich MJ Schwaber AW Karchmer Y Carmeli 2003 Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis Clin Infect Dis 36 53 59 10.1086/345476 12491202
3. K Hiramatsu H Hanaki T Ino K Yabuta T Oguri FC Tenover 1997 Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility J Antimicrob Chemother 40 135 136 1:CAS:528: DyaK2sXltVCit7w%3D 10.1093/jac/40.1.135 9249217
4. Y Maor G Rahav N Belausov D Ben-David G Smollan N Keller 2007 Prevalence and characteristics of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia in a tertiary care center J Clin Microbiol 45 1511 1514 1:CAS:528:DC%2BD2sXmsFOmtLY%3D 10.1128/JCM.01262-06 17344363
5. MW Climo RL Patron GL Archer 1999 Combinations of vancomycin and beta-lactams are synergistic against staphylococci with reduced susceptibilities to vancomycin Antimicrob Agents Chemother 43 1747 1753 1:CAS:528: DyaK1MXktlCksbk%3D 10390234
6. A Domenech S Ribes C Cabellos MA Domínguez A Montero J Liñares, et al. 2004 A mouse peritonitis model for the study of glycopeptide efficacy in GISA infections Microb Drug Resist 10 346 353 1:CAS:528:DC%2BD2MXhsFakuro%3D 10.1089/mdr.2004.10.346 15650381
7. MR Moore F Perdreau-Remington HF Chambers 2003 Vancomycin treatment failure associated with heterogeneous vancomycin-intermediate Staphylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis Antimicrob Agents Chemother 47 1262 1266 1:CAS:528:DC%2BD3sXivVSnu7w%3D 10.1128/AAC.47.4.1262-1266.2003 12654656
8. J Ariza M Pujol J Cabo C Peña N Fernández J Liñares, et al. 1999 Vancomycin in surgical infections due to methicillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin Lancet 8 1587 1588 10.1016/S0140-6736(99)01017-X
9. N Aritaka H Hanaki L Cui K Hiramatsu 2001 Combination effect of vancomycin and beta-lactams against a Staphylococcus aureus strain, Mu3, with heterogeneous resistance to vancomycin Antimicrob Agents Chemother 45 1292 1294 1:CAS:528:DC%2BD3MXit1Omsb4%3D 10.1128/AAC.45.4.1292-1294.2001 11257050
10. FW Goldstein R Atoui A Ben Ali JC Nguyen A Ly MD Kitzis 2004 False synergy between vancomycin and beta-lactams against glycopeptide-intermediate Staphylococcus aureus (GISA) caused by inappropriate testing methods Clin Microbiol Infect 10 342 345 1:CAS:528:DC%2BD2cXktlamurk%3D 10.1111/j.1198-743X. 2004.00856.x 15059127
11. RH Drew 2007 Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections Pharmacotherapy 27 227 249 1:CAS:528:DC%2BD2sXitlyjsb8%3D 10.1592/phco.27.2.227 17253914
12. JR Lentino M Narita VL Yu 2008 New antimicrobial agents as therapy for resistant gram-positive cocci Eur J Clin Microbiol Infect Dis 27 3 15 1:CAS:528:DC%2BD2sXhtlOis7vO 10.1007/s10096-007-0389-y 17899228
13. MJ Rybak E Hershberger T Moldovan RG Grucz 2000 In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin-intermediate and -resistant strains Antimicrob Agents Chemother 44 1062 1066 1:CAS:528:DC%2BD3cXitFOksrs%3D 10.1128/AAC.44.4.1062-1066.2000 10722513
14. CM Perry B Jarvis 2001 Linezolid: a review of its use in the management of serious gram-positive infections Drugs 61 525 551 1:CAS:528: DC%2BD3MXjsFSgsbc%3D 10.2165/00003495-200161040-00008 11324682
15. E Rubinstein S Cammarata T Oliphant R Wunderink 2001 Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study Clin Infect Dis 32 402 412 1:CAS:528:DC%2BD3MXhs1Whur0%3D 10.1086/318486 11170948
16. DL Stevens D Herr H Lampiris JL Hunt DH Batts B Hafkin 2002 Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections Clin Infect Dis 34 1481 1490 1:CAS:528:DC%2BD38XltFamtrk%3D 10.1086/340353 12015695
17. RN Jones TR Fritsche HS Sader JE Ross 2007 Zyvox Annual Appraisal of Potency and Spectrum Program Results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from 16 countries Diagn Microbiol Infect Dis 59 199 209 1:CAS:528:DC%2BD2sXhtFSksLrE 10.1016/j.diagmicrobio.2007.06.001 17908617
18. P Wilson JA Andrews R Charlesworth R Walesby M Singer DJ Farrell, et al. 2003 Linezolid resistance in clinical isolates of Staphylococcus aureus J Antimicrob Chemother 51 186 188 1:CAS:528:DC%2BD38XpslOgtL0%3D 10.1093/jac/dkg104 12493812
19. C Jacqueline J Caillon V Le Mabecque AF Miègeville A Hamel D Bugnon, et al. 2007 In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model Antimicrob Agents Chemother 51 3397 3400 1:CAS:528:DC%2BD2sXhtVais7bN 10.1128/AAC.01242-06 17591849
20. M Sacar S Sacar I Kaleli G Onem H Turgut I Goksin, et al. 2007 Linezolid alone and in combination with rifampicin prevents experimental vascular graft infection due to methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis J Surg Res 139 170 175 1:CAS:528:DC%2BD2sXktF2ktbc%3D 10.1016/j.jss.2006.10.003 17292421
21. Clinical and Laboratory Standards Institute (CLSI) (2005) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A6, 6th ed. CLSI, Wayne, PA
22. AP MacGowan 2003 Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections J Antimicrob Chemother 51 Suppl 2 ii17 ii25 1:CAS:528:DC%2BD3sXktlOquro%3D 12730139
23. A Domenech S Ribes C Cabellos F Taberner F Tubau MA Domínguez, et al. 2005 Experimental study on the efficacy of combinations of glycopeptides and beta-lactams against Staphylococcus aureus with reduced susceptibility to glycopeptides J Antimicrob Chemother 56 709 716 1:CAS:528:DC%2BD2MXhtVKiu7bF 10.1093/jac/dki294 16120625
24. MJ Gentry-Nielsen KM Olsen LC Preheim 2002 Pharmacodynamic activity and efficacy of linezolid in a rat model of pneumococcal pneumonia Antimicrob Agents Chemother 46 1345 1351 1:CAS:528:DC%2BD38XjtFKksbk%3D 10.1128/AAC.46.5.1345- 1351.2002 11959567
25. JD Knudsen K Fuursted F Espersen N Frimodt-Møller 1997 Activities of vancomycin and teicoplanin against penicillin-resistant pneumococci in vitro and in vivo and correlation to pharmacokinetic parameters in the mouse peritonitis model Antimicrob Agents Chemother 41 1910 1915 1:CAS:528: DyaK2sXlvFOgtLc%3D 9303383
26. O Murillo A Doménech A Garcia F Tubau C Cabellos F Gudiol, et al. 2006 Efficacy of high doses of levofloxacin in experimental foreign-body infection by methicillin-susceptible Staphylococcus aureus Antimicrob Agents and Chemother 50 4011 4017 1:CAS:528:DC%2BD28XhtlWksrvO 10.1128/AAC.00523-06
27. D Paradis F Vallée S Allard C Bisson N Daviau Ch Drapeau, et al. 1992 Comparative study of pharmacokinetics and serum bactericidal activities of cefpirome, ceftazidime, ceftriaxone, imipenem, and ciprofloxacin Antimicrob Agents Chemother 36 2085 2092 1:CAS:528:DyaK3sXjt1GmtQ%3D%3D 1444289
28. C Jacqueline D Navas E Batard AF Miègeville V Le Mabecque MF Kergueris, et al. 2005 In vitro and in vivo synergistic activities of linezolid combined with subinhibitory concentrations of imipenem against methicillin-resistant Staphylococcus aureus Antimicrob Agents Chemother 49 45 51 1:CAS:528:DC%2BD2MXjsl2qsA%3D%3D 10.1128/AAC.49.1.45-51.2005 15616274
29. C Jacqueline J Caillon V Le Mabecque AF Miègeville PY Donnio D Bugnon, et al. 2003 In vitro activity of linezolid alone and in combination with gentamicin, vancomycin or rifampicin against methicillin-resistant Staphylococcus aureus by time-kill curve methods J Antimicrob Chemother 51 857 864 1:CAS:528:DC%2BD3sXisleks7w%3D 10.1093/jac/dkg160 12654769
30. JM Sahuquillo Arce E Colombo Gainza A Gil Brusola R Ortiz Estévez E Cantón M Gobernado 2006 In vitro activity of linezolid in combination with doxycycline, fosfomycin, levofloxacin, rifampicin and vancomycin against methicillin-susceptible Staphylococcus aureus Rev Esp Quimioter 19 252 257 1:STN:280:DC%2BD28nmvVehsQ%3D%3D 17099793
31. GP Allen R Cha MJ Rybak 2002 In vitro activities of quinupristin- dalfopristin and cefepime, alone and in combination with various antimicrobials, against multidrug-resistant staphylococci and enterococci in an in vitro pharmacodynamic model Antimicrob Agents Chemother 46 2606 2612 1:CAS:528:DC%2BD38XlsFGitLg%3D 10.1128/AAC.46.8.2606-2612.2002 12121940
32. S Tsiodras HS Gold G Sakoulas GM Eliopoulos C Wennersten L Venkataraman, et al. 2001 Linezolid resistance in a clinical isolate of Staphylococcus aureus Lancet 358 207 208 1:CAS:528:DC%2BD3MXltlymsr8%3D 10.1016/S0140-6736(01)05410-1 11476839
33. B Fantin C Carbon 1992 In vivo antibiotic synergism: contribution of animal models Antimicrob Agents Chemother 36 907 912 1:CAS:528: DyaK38XisVOkurY%3D 1510412
34. BA Cunha 2005 Methicillin-resistant Staphylococcus aureus: clinical manifestations and antimicrobial therapy Clin Microbiol Infect 11 33 42 1:CAS:528:DC%2BD2MXms1ehsbk%3D 10.1111/j.1469-0691.2005.01162.x 15997484